Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia

Pharmacotherapy

Volumn 20, Issue 8I, 2000, Pages 974-980

  Andreescu, Astrid C M ^a   Possidente, Carl ^b   Hsieh, Matthew ^c   Cushman, Mary ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ARTICLE; CANCER; DRUG SURVEILLANCE PROGRAM; HUMAN; INCIDENCE; PHARMACIST; PHARMACY; RISK FACTOR; SEROLOGY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PHARMACY SERVICE, HOSPITAL; PLATELET COUNT; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033847602     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.11.974.35264     Document Type: Article

References (26)

1. Interaction of heparin with platelets, including heparin-induced thrombocytopenia
2. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin
3. A 14-year study of heparin-induced thrombocytopenia
4. Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis
5. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation
6. The mechanism of heparin-induced platelet aggregation
7. Characterization of the humoral immune response in heparin-induced thrombocytopenia
8. Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution
9. Heparin induced thrombocytopenia and thrombosis: Clinical and laboratory studies
10. Heparin induced thrombocytopenia with thrombosis: Frequency, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
11. Heparin-associated thrombocytopenia (HAT) - Still a diagnostic and therapeutical problem in clinical practice
12. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia
13. A diagnostic test for heparin-induced thrombocytopenia
14. Diagnostic testing for heparin-induced thrombocytopenia (HIT): An enhanced platelet factor 4 complex enzyme linked immunosorbent assay (PF4 ELISA)
15. Antibodies associated with heparin-induced thrombocytopenia (HIT) report conformational changes in platelet factor four (PF4) induced by linear, polyanionic compounds
16. Blood coagulation and cancer: From Trousseau's syndrome to angiogenesis
17. Cancer and thrombosis
18. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
19. Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: A prospective, historical controlled study
20. Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy
21. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients
22. Outcome analysis of a pharmacist-managed anticoagulation service
23. Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions
24. Pharmacist-directed heparin therapy using a standard dosing and monitoring protocol
25. Pharmacy-managed, weight-based heparin protocol
26. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service